Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment

Ala Moshiri, Nguyen Khoi Ha, Fang S. Ko, Adrienne Scott

Research output: Contribution to journalArticle

Abstract

Purpose: To report the use of presurgical intravitreal bevacizumab in the context of proliferative sickle-cell retinopathy with retinal detachment. Methods: Intravitreal bevacizumab was injected 3 days before the surgical procedure for traction retinal detachment. Vitrectomy, membrane peeling, endolaser, and SF6 gas tamponade were performed. A 37-year-old African American woman presented with hemoglobin sickle-cell disease and temporal retinal detachment with bullous subretinal fluid extending through the fovea associated with an area of active sea-fan retinal neovascularization with preretinal hemorrhage and retinal traction, with 3 associated retinal breaks. Results: The sea-fan neovascularization associated with the traction retinal detachment and the resultant retinal breaks appeared more fibrotic and les vascular than was noted prior to the pre-operative bevacizumab injection. Segmentation and dissection were performed with minimal bleeding, and retinal traction was relieved without difficulty. This was believed to be atypical in the experience of the surgeons. One month postoperatively, vision measured 20/50, and the retina remained attached. Conclusion: Further study is necessary to clarify the role of anti-vascular endothelial growth factor in the treatment of proliferative sickle cell retinopathy associated retinal detachment.

Original languageEnglish (US)
Pages (from-to)204-205
Number of pages2
JournalRetinal Cases and Brief Reports
Volume7
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Retinal Detachment
Traction
Retinal Perforations
Oceans and Seas
Retinal Neovascularization
Subretinal Fluid
Retinal Hemorrhage
Therapeutics
Vitrectomy
Sickle Cell Anemia
African Americans
Vascular Endothelial Growth Factor A
Blood Vessels
Retina
Dissection
Hemoglobins
Gases
Bevacizumab
Hemorrhage
Injections

Keywords

  • Anti-vascular endothelial growth factor
  • Bevacizumab
  • Sickle-cell retinopathy
  • Traction retinal detachment

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment. / Moshiri, Ala; Ha, Nguyen Khoi; Ko, Fang S.; Scott, Adrienne.

In: Retinal Cases and Brief Reports, Vol. 7, No. 3, 06.2013, p. 204-205.

Research output: Contribution to journalArticle

@article{f7499899d55a4a87b278168705f5510d,
title = "Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment",
abstract = "Purpose: To report the use of presurgical intravitreal bevacizumab in the context of proliferative sickle-cell retinopathy with retinal detachment. Methods: Intravitreal bevacizumab was injected 3 days before the surgical procedure for traction retinal detachment. Vitrectomy, membrane peeling, endolaser, and SF6 gas tamponade were performed. A 37-year-old African American woman presented with hemoglobin sickle-cell disease and temporal retinal detachment with bullous subretinal fluid extending through the fovea associated with an area of active sea-fan retinal neovascularization with preretinal hemorrhage and retinal traction, with 3 associated retinal breaks. Results: The sea-fan neovascularization associated with the traction retinal detachment and the resultant retinal breaks appeared more fibrotic and les vascular than was noted prior to the pre-operative bevacizumab injection. Segmentation and dissection were performed with minimal bleeding, and retinal traction was relieved without difficulty. This was believed to be atypical in the experience of the surgeons. One month postoperatively, vision measured 20/50, and the retina remained attached. Conclusion: Further study is necessary to clarify the role of anti-vascular endothelial growth factor in the treatment of proliferative sickle cell retinopathy associated retinal detachment.",
keywords = "Anti-vascular endothelial growth factor, Bevacizumab, Sickle-cell retinopathy, Traction retinal detachment",
author = "Ala Moshiri and Ha, {Nguyen Khoi} and Ko, {Fang S.} and Adrienne Scott",
year = "2013",
month = "6",
doi = "10.1097/ICB.0b013e3182845d31",
language = "English (US)",
volume = "7",
pages = "204--205",
journal = "Retinal Cases and Brief Reports",
issn = "1935-1089",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment

AU - Moshiri, Ala

AU - Ha, Nguyen Khoi

AU - Ko, Fang S.

AU - Scott, Adrienne

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: To report the use of presurgical intravitreal bevacizumab in the context of proliferative sickle-cell retinopathy with retinal detachment. Methods: Intravitreal bevacizumab was injected 3 days before the surgical procedure for traction retinal detachment. Vitrectomy, membrane peeling, endolaser, and SF6 gas tamponade were performed. A 37-year-old African American woman presented with hemoglobin sickle-cell disease and temporal retinal detachment with bullous subretinal fluid extending through the fovea associated with an area of active sea-fan retinal neovascularization with preretinal hemorrhage and retinal traction, with 3 associated retinal breaks. Results: The sea-fan neovascularization associated with the traction retinal detachment and the resultant retinal breaks appeared more fibrotic and les vascular than was noted prior to the pre-operative bevacizumab injection. Segmentation and dissection were performed with minimal bleeding, and retinal traction was relieved without difficulty. This was believed to be atypical in the experience of the surgeons. One month postoperatively, vision measured 20/50, and the retina remained attached. Conclusion: Further study is necessary to clarify the role of anti-vascular endothelial growth factor in the treatment of proliferative sickle cell retinopathy associated retinal detachment.

AB - Purpose: To report the use of presurgical intravitreal bevacizumab in the context of proliferative sickle-cell retinopathy with retinal detachment. Methods: Intravitreal bevacizumab was injected 3 days before the surgical procedure for traction retinal detachment. Vitrectomy, membrane peeling, endolaser, and SF6 gas tamponade were performed. A 37-year-old African American woman presented with hemoglobin sickle-cell disease and temporal retinal detachment with bullous subretinal fluid extending through the fovea associated with an area of active sea-fan retinal neovascularization with preretinal hemorrhage and retinal traction, with 3 associated retinal breaks. Results: The sea-fan neovascularization associated with the traction retinal detachment and the resultant retinal breaks appeared more fibrotic and les vascular than was noted prior to the pre-operative bevacizumab injection. Segmentation and dissection were performed with minimal bleeding, and retinal traction was relieved without difficulty. This was believed to be atypical in the experience of the surgeons. One month postoperatively, vision measured 20/50, and the retina remained attached. Conclusion: Further study is necessary to clarify the role of anti-vascular endothelial growth factor in the treatment of proliferative sickle cell retinopathy associated retinal detachment.

KW - Anti-vascular endothelial growth factor

KW - Bevacizumab

KW - Sickle-cell retinopathy

KW - Traction retinal detachment

UR - http://www.scopus.com/inward/record.url?scp=84887884561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887884561&partnerID=8YFLogxK

U2 - 10.1097/ICB.0b013e3182845d31

DO - 10.1097/ICB.0b013e3182845d31

M3 - Article

C2 - 25391106

AN - SCOPUS:84887884561

VL - 7

SP - 204

EP - 205

JO - Retinal Cases and Brief Reports

JF - Retinal Cases and Brief Reports

SN - 1935-1089

IS - 3

ER -